Koios secures CE Mark for cancer diagnosis ultrasound software

2022 12 05 19 15 5859 Ce Mark Business 400

Koios Medical has secured the European CE Mark for its thyroid and breast cancer diagnosis ultrasound software.

The software incorporates data from 55 sites to support quick and accurate diagnosis, automate reporting, and reduce time to treatment, the company said. It is cleared by the U.S. Food and Drug Administration (FDA) and has been available in the U.S. since late 2021; this year, it was assigned CPT Category III billing codes.

Page 1 of 109
Next Page